PainDETECT as a Potential Tool for Personalized Medicine: Predicting Outcome One Year After Knee Arthroplasty
Wall AJW. et al, (2025), Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 9, 100649 - 100649
Brain signatures of nociplastic pain: Fibromyalgia Index and descending modulation at population level
Kelleher EM. et al, (2025), Brain
Systematic review and co-ordinate based meta-analysis to summarize the utilization of functional brain imaging in conjunction with human models of peripheral and central sensitization.
Clarke S. et al, (2024), Eur J Pain, 28, 1069 - 1094
CENTRALISED PAIN IN EARLY RHEUMATOID ARTHRITIS PREDICTS WORSE BODILY PAIN OUTCOMES
Kelleher E. et al, (2024), RHEUMATOLOGY, 63, I74 - I74
THE USE OF ONLINE PLATFORMS IN THE TREATMENT OF CHRONIC MUSCULOSKELETAL DISEASE
Wall AJW. et al, (2024), RHEUMATOLOGY, 63, I146 - I146
Hippocampus mediates nocebo impairment of opioid analgesia through changes in functional connectivity
Bingel U. et al, (2022), European Journal of Neuroscience, 56, 3967 - 3978
IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET).
Nochi Z. et al, (2022), Trials, 23
IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG).
Mouraux A. et al, (2021), Trials, 22
"Consensus on Placebo and Nocebo Effects Connects Science with Practice:" Reply to "Questioning the Consensus on Placebo and Nocebo Effects".
Evers AWM. et al, (2021), Psychother Psychosom, 90, 213 - 214
What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus.
Evers AWM. et al, (2021), Psychother Psychosom, 90, 49 - 56
Response to "Treating patients rather than their functional neuroimages" (Br J Anaesth 2018; 121: 969-71).
Wanigasekera V. et al, (2019), Br J Anaesth, 123, e166 - e171
Opioids for breathlessness: Psychological and neural factors influencing response variability
Abdallah S. et al, (2019), European Respiratory Journal
Central Sensitization in Knee Osteoarthritis: Relating Presurgical Brainstem Neuroimaging and PainDETECT‐Based Patient Stratification to Arthroplasty Outcome
Soni A. et al, (2019), Arthritis & Rheumatology, 71, 550 - 560
Sertraline or placebo in chronic breathlessness? Lessons from placebo research.
Pattinson K. and Wanigasekera V., (2019), Eur Respir J, 53
Validation of an FMRI Based Classification Pipeline for Detecting Analgesic Efficacy from Neuroimaging Data
WANIGASEKERA V. et al, (2018)
Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging
Wanigasekera V. et al, (2018), British Journal of Anaesthesia, 120, 299 - 307
Opioids decrease the unpleasantness of dyspnoea via actions in the medial prefrontal cortex
Hayen A. et al, (2017), Biological Psychology, 129, 375 - 376